Davis R M Inc. cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,552 shares of the company's stock after selling 3,563 shares during the period. Davis R M Inc.'s holdings in Zoetis were worth $21,108,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. State Street Corp raised its holdings in shares of Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock worth $2,030,813,000 after buying an additional 185,364 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Zoetis by 8.5% in the fourth quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company's stock valued at $906,202,000 after acquiring an additional 433,429 shares in the last quarter. Mizuho Securities USA LLC increased its position in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Zoetis by 5.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after acquiring an additional 194,542 shares during the last quarter. Institutional investors own 92.80% of the company's stock.
Insider Buying and Selling at Zoetis
In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last quarter. Company insiders own 0.16% of the company's stock.
Zoetis Stock Performance
Shares of NYSE:ZTS traded down $2.14 during midday trading on Wednesday, reaching $162.25. 1,395,490 shares of the company traded hands, compared to its average volume of 2,569,664. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The firm's fifty day moving average price is $166.94 and its two-hundred day moving average price is $176.55. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $72.66 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.
Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. Zoetis's dividend payout ratio is currently 36.56%.
Analyst Ratings Changes
A number of research analysts have issued reports on ZTS shares. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $215.90.
Read Our Latest Research Report on ZTS
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
